Orexo's Transformation Gets a Term Sheet—and a Bill

The DOJ settlement and Izipry refiling clear two overhangs, but the rights issue turns the platform story into a financing test.

ORX.ST · Earnings Call · 2026-10-22

Orexo's Transformation Gets a Term Sheet—and a Bill

For a company that spent the past year selling its commercial business, Orexo's Q3 report reads less like a pipeline update and more like a closing statement. CEO Nikolaj Sørensen calls it “Orexo in Transformation” — Nikolaj Sørensen, CEO · 2026-10-22, and the keyword trail confirms it: rights issue, cash burn, Zubsolv rebates, and Department of Justice dominate the quarter. The science is still there, but the story has shifted from what AmorphOX can become to who pays for it.

The DOJ Overhang Finally Gets a Term Sheet

The biggest change is legal. In July, the company was still describing “very concrete discussions about a concrete term sheet with the DOJ” — Nikolaj Sørensen, CEO · 2026-07-16, but no signed agreement. This quarter, Sørensen says they have “agreed in principle on the main terms with Department of Justice” — Nikolaj Sørensen, CEO · 2026-10-22. The provision is up to $4 million over several years, with the first installment delayed by administrative process. That is a massive de-risking relative to the >$10 million litigation cost the CEO flagged in July. It also unlocks the financing door: in July, management said they would need clarity around the DOJ before raising equity. Now the rights issue is live. But note the nuance: Orexo is “not in a super hurry” — Nikolaj Sørensen, CEO · 2026-10-22 because it has an agreement in place, and any delay also delays the first payment. That is a company managing cash, not a company celebrating. The DOJ is no longer a cliff; it is a scheduled payable.

Izipry: A Six-Month Clock and a Different Partner Set

Izipry was resubmitted to the FDA on September 29. Management expects a six-month review, putting approval at the end of Q1 2027. The review process is now the value inflection point. The partnering process is already running, but Sørensen is explicit that the counterparties change after approval: “there are definitely a different set of companies who would be interested in products that are approved” — Nikolaj Sørensen, CEO · 2026-10-22. That is a familiar biotech trade-off: wait for the label and get a better deal, or partner now and fund the wait. Orexo is choosing to wait, which is brave given the cash position.

OX640: The Pivotal Trial Is Real, the Partner Is Not

The pivotal trial for OX640 is the company's largest near-term value driver. The IND was accepted, 12,000 commercial-scale units were manufactured, and the nasal allergen challenge study is expected to start this quarter, with data in H1 2027. The company is funding this stage itself; the final pivotal program is explicitly expected to be partner-funded: “we are expecting that is coming out of this partnering agreement” — Nikolaj Sørensen, CEO · 2026-10-22. That is a clean story if the partner signs. If not, the cash burn becomes the story.

The Cash Math Is the Real Tension

The headline cash number is SEK 153 million. The economic number is SEK 62 million. CFO Fredrik Järrsten lays it out: funds payable to Dexcel were SEK 65 million and Zubsolv rebates in payables were SEK 26 million. That is the quarter's most important disclosure, and it explains why the rights issue is not opportunistic.

Out of the total cash and cash equivalents end of Q3 of SEK 153 million, funds payable to Dexcel was SEK 65 million and rebates in account payables related to Zubsolv amounted to SEK 26 million. That meant that Orexo's own cash end of Q3 amounted to SEK 62 million.
Fredrik Järrsten, CFO · 2026-10-22

Against a normalized OpEx run-rate of SEK 18 million per month, that is thin. Management argues 70% of Q3 outflows were non-recurring, and the earn-out from Zubsolv is expected in Q1. But the market will focus on the pro forma cash, not the accounting explanation. The Q2 call had already hinted at this: “our current valuation is not optimal” — Nikolaj Sørensen, CEO · 2026-07-16, Sørensen said, while also arguing that partners want a strong balance sheet. The rights issue is the answer to that tension. Back in February, the company said it was “well capitalized” — Nikolaj Sørensen, CFO · 2026-02-05 with money to run current projects. That language is gone. The new language is runway past 2027 — with cost cuts, earn-out, and partnership proceeds all stacked.

Semaglutide: The Quiet Optionality

The most interesting scientific nugget is easy to miss. Orexo's first oral tablet using AmorphOX showed comparable bioavailability to the reference tablet. That is not a home run — Sørensen admits “to be excellent, we need to have better bioavailability” — Nikolaj Sørensen, CEO · 2026-10-22 — but it is a credible proof point for the platform beyond nasal rescue products. The existing industry partner is interested in expanding into other routes of administration. If that turns into a signed deal, it would validate the AmorphOX technology as a partnering platform, not just a pipeline of two assets. For now, it sits below the financing noise in the keyword stack, which is appropriate: it is optionality, not a catalyst.

What Changed, and What Didn't

What changed: the DOJ went from negotiation to agreement in principle; Izipry went from delayed to filed; OX640 went from planning to commercial batch and trial start; and the company replaced well capitalized with a rights issue. What didn't: the partnering deals are still unsigned. The company is still asking investors to fund the last mile. And the keyword list still ranks staff reductions and administrative cost above partnership. That is the honest read of the quarter: Orexo has moved from turnaround to financing event. The platform story is intact, but the balance sheet is now the protagonist.